Ziprasidone in treatment-resistant schizophrenia: A 52-week, open-label continuation study

Journal of Clinical Psychiatry

Volumn 68, Issue 9, 2007, Pages 1333-1338

  Loebel, Antony D ^a   Khanna, Sumant ^b   Rajadhyaksha, Sunita ^a   Siu, Cynthia O ^c   Giller, Earl ^a   Potkin, Steven G ^d  

^a PFIZER INC   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^c Data Power DP Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; DIURETIC AGENT; FLURAZEPAM; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; HORMONE DERIVATIVE; LORAZEPAM; ORAL ANTIDIABETIC AGENT; ZIPRASIDONE;

AKATHISIA; ANOREXIA; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; HUMAN; INSOMNIA; LABORATORY TEST; LONG TERM CARE; MOTOR DYSFUNCTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA;

EID: 34948850922     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0902     Document Type: Article

References (28)

1. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001;50:898-911
2. Kane J, Honigfeld G, Singer J, et al. Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
3. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-1752
4. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. N Engl J Med 1993;329:162-167
5. Lieberman JA, Johns CA, Kane JM, et al. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 1988;49:271-277
6. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-262
7. Chakos M, Lieberman J, Hoffman J, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-526
8. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-920
9. Breier A, Hamilton S. Comparative efficacy ofolanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999;45:403-411
10. Kane JM, Khanna S, Rajadhyaksha S, et al. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2006;21:21-28
11. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
12. Kay SR, Opler LA, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health System; 1986
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
14. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(suppl 212):11-19
15. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
16. Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
17. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
18. Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005;162:1535-1538
19. Geodon [package insert]. New York, NY: Pfizer; 2006
20. Dhavale HS, Pinto C, Dass J, et al. Prophylaxis of antipsychotic-induced extrapyramidal side effects in east Indians: cultural practice or biological necessity? J Psychiatr Pract 2004;10:200-202
21. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med 2005;353:1209-1223
22. Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:1837-1847
23. Weiden PJ, Daniel DG, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003;23:595-600
24. Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry 2001;62(suppl 27):35-39
25. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 2005;10:S1-S20
26. Deutschman DA, Deutschman DH. High-dose ziprasidone: efficacy and tolerability in clinical practice. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
27. Arato M, O'Connor R, Meltzer H. The Ziprasidone Extended Use in Schizophrenia (ZEUS) study: a double-blind, placebo-controlled, 1-year clinical trial. Int Clin Psychopharmacol 2002;17:207-215
28. Hirsch S, Kissling W, Bauml J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63:516-523